Lisocabtagene Maraleucel,ibrutinib,venetoclax
Bms,Roche,Abbvie
['cll']
 depends what the comparison is compared to other malignancies, of course those response rates are disappointing compared to previous trials in cll, it does seem like some progress in the right direction, especially with regards to manufacturing #asco23
haematology registrar | @harvardmed fellow @PORTAL_research | evidence-based medicine & policy | lymphoma | myeloma | Fulbright | writer | SoMe Ed @BrJHaem